Evaluation of the maternal–fetal transfer of granisetron in an ex vivo placenta perfusion model
•Observed that granisetron has concentration dependent placental transfer.•At systemic granisetron concentrations achieved with IV administration, fetal exposure was greater than 30ng/mL.•At systemic granisetron concentrations achieved with transdermal patch, there was no placental transfer detected...
Gespeichert in:
Veröffentlicht in: | Reproductive toxicology (Elmsford, N.Y.) N.Y.), 2014-11, Vol.49, p.43-47 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Observed that granisetron has concentration dependent placental transfer.•At systemic granisetron concentrations achieved with IV administration, fetal exposure was greater than 30ng/mL.•At systemic granisetron concentrations achieved with transdermal patch, there was no placental transfer detected.
The objective of this study was to estimate maternal–fetal transplacental passage of granisetron in an ex vivo placental perfusion model. Term human placentas (N=8) were collected immediately after delivery. A single cotyledon from each placenta was perfused granisetron concentration to mimic systemic maternal peak plasma concentrations following either IV (50ng/mL) or transdermal administration (5ng/mL). To assess drug transfer and accumulation, samples were collected from maternal and fetal compartments.
In the 50ng/mL open model, the mean transport fraction was 0.21±0.08 with clearance index of 0.53±0.66. Fetal peak concentrations achieved was 5.6±6.6ng/mL with mean accumulation of 5.35±6.4ng/mL. No drug was detected in the fetal compartment with the 5ng/mL models.
Transplacental passage of granisetron was inconsistent at the 50ng/mL concentration that achieved with IV dosing. However, there consistently was no detectable passage in all the placentas evaluated of the granisetron at 5ng/mL concentration that would be achieved after transdermal patch administration. |
---|---|
ISSN: | 0890-6238 1873-1708 |
DOI: | 10.1016/j.reprotox.2014.06.003 |